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Acute inflammation is a normal response 
to infection and is beneficial for the host 
to survive. However, most human diseases 
are due to sterile inflammation. When 
allowed to continue unchecked, sterile 
inflammation can result in autoinflamma-
tory disorders, neurodegenerative disease, 
or cancer. A variety of safe and effective 
anti-inflammatory agents are available 
for short term control of acute inflamma-
tion including aspirin and non-steroidal 
anti-inflammatory drugs (NSAIDs). For 
the most part, even short term glucocor-
ticoids are safe and effective. But attacking 
the upstream causes of inflammation is 
required for long-term treatment. There is 
new era of anti-inflammatory agents, which 
includes “biologicals” such as anti-cytokine 
therapies, kinase inhibitors, statins, histone 
deacetylase inhibitors, and PPAR agonists.
Reducing pain, inflammation, and fever 
with salicylate-containing plant extracts 
can be traced throughout written human 
history. One hundred fifty years ago, Felix 
Hoffman acetylated salicylic acid and cre-
ated aspirin. Aspirin inhibits the cyclooxy-
genase (COX) enzymes COX-1 and COX-2, 
which synthesize the inflammatory media-
tors prostaglandins and thromboxanes. 
The ability to block production of pros-
taglandins and thromboxanes accounts 
for aspirin being the world’s most used 
therapeutic agent. Second to aspirin are 
NSAIDs, which target COX-2 and hence 
the synthesis of prostaglandins, particularly 
PGE2. Synthetic forms of natural cortisol 
(termed glucocorticoids) are widely used 
to treat many inflammatory diseases and 
despite their serious side effects, glucocor-
ticoids remain a mainstay of inflammation 
reduction. Yet, it is still the challenge of the 
pharmaceutical chemist to develop more 
effective and less toxic agents to treat the 
signs and symptoms of acute inflammation 
as well as the long-term consequences of 
chronic inflammatory diseases.
Inflammation is a dynamic process with 
pro-inflammatory cytokines such as tumor 
necrosis factor (TNF)-α and interleukin 
(IL)-1 playing central roles. A number of 
“biologicals” have been developed to treat 
inflammation by reducing the activity of 
specific cytokines or their receptors (anti-
cytokine therapies), block lymphocyte 
trafficking into tissues, prevent the bind-
ing of monocyte–lymphocyte co-stimula-
tory molecules, or deplete B lymphocytes. 
Current anti-cytokine therapies have found 
a place in the treatment of autoimmune dis-
eases, such as rheumatoid arthritis, inflam-
matory bowel disease, psoriasis, and others. 
Without question, neutralization of specific 
pro-inflammatory cytokines has demon-
strated their causative role in inflamma-
tion and has changed the lives of millions 
of patients with these diseases. One draw-
back of anti-cytokine therapies is decreased 
host immune defense against infection and 
possibly cancer. Nevertheless, the benefits of 
anti-cytokine therapies outweigh the risks 
and the risks can be reduced. Compared 
to the consequences of long-term gluco-
corticoid treatment to stem inflamma-
tion, anti-cytokine therapies are a major 
improvement. Indeed, organ toxicities are 
rarely, if ever, observed with anti-cytokine 
therapies as they operate almost exclusively 
in extracellular rather than intracellular 
compartments.
Kinases that act downstream of cytokine 
receptors have become new targets to tame 
inflammation, and orally active small mol-
ecule inhibitors of intracellular signaling 
kinases will likely be the new frontier of anti-
inflammatory agents. However, because 
many intracellular signaling molecules are 
involved in normal cellular functions, the 
effective concentration that does not elicit 
organ toxicity will need to be carefully deter-
mined. Statins, a safe class of drugs used 
for lowering serum cholesterol, also have 
anti-inflammatory properties. Orally active 
inhibitors of histone deacetylases, which are 
currently in clinical use, are effective anti-
inflammatory drugs. Naturally occurring 
resolvins are also being developed as anti-
inflammatory agents. Thus the challenge is 
to develop anti-inflammatory agents that 
are orally active, safe, and effective for treat-
ing acute or chronic inflammation.
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